SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is gaining traction as a meme coin on the Injective ($INJ) network, with community members highlighting its strong performance relative to $INJ and its robust, active community.  Discussion revolves around its potential for high returns, especially with the upcoming Injective EVM mainnet and potential ETFs, and the unique qualities of its NFT collections.  The community emphasizes $NONJA's strong fundamentals, burned liquidity, and status as a leading meme coin on the $INJ ecosystem.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending amid discussions about its strategic shift towards AI and robotics, with the unveiling of the 'Iron' humanoid robot driving significant investor interest. The community is actively discussing the potential for XPEV to become a leader in physical AI, expanding beyond its current EV focus, with some comparing it favorably to Tesla. Bullish sentiment is also supported by strong delivery numbers and expansion into new global markets.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding the release of Epstein files and their potential implications for Trump. The community is focused on speculation about Trump's connections and any efforts to suppress the release. Political divides are fueling the conversation, with some questioning motives and potential impacts.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending amid discussions about its recent earnings, investor day, and potential for a short squeeze. Community members are focused on the company's growth prospects in Africa and its path to profitability, with some expressing optimism about long-term targets and potential institutional investment. Bullish sentiment is fueled by perceived undervaluation and the stock's uncorrelated nature to other markets.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to positive sentiment around a potential acquisition by Merck for $9.2B, which sent the stock soaring. The community is discussing the impact of the deal on options, what happens to shares post-acquisition, and whether a bidding war might further increase the acquisition price. Some investors are also looking at similar companies that may be acquisition targets.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as the community discusses Warren Buffett's firm taking a new multi-billion dollar stake in Google's parent company, Alphabet, signaling a bet on AI and growth stocks. This move has sparked debate, with some seeing it as a smart shift away from Apple, while others question the timing and Buffett's value investing principles. The investment comes amidst market context showing a bullish trend for Berkshire, although the stock is nearing overbought territory.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending due to market uncertainty fueled by renewed US-China trade tensions and a broader tech sell-off; the immediate catalyst seems to be Trump's tariff threats, sparking fears of a deeper trade war. The community is actively discussing potential support levels, dip-buying opportunities, and whether this is a temporary pullback or the start of a larger correction, with some drawing comparisons to previous market crashes. There are mixed sentiments with some investors remaining bullish on the long-term prospects of tech and AI while others express concerns about inflated valuations and the potential impact of a prolonged government shutdown.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.</li><li>The proposal includes amending the ongoing VERSATILE-003 Phase 3 study to add progression-free survival as an earlier primary endpoint, potentially allowing for an earlier submission.</li><li>Retail traders on Stocktwits flooded discussions with optimism, calling the stock “too cheap” and speculating that the FDA could grant early approval to give patients faster access to the therapy.</li></ul>Shares of PDS Biotechnology logged their best session in more than two months after the late-stage immunotherapy company said it has requested a meeting with the U.S. Food and Drug Administration to discuss an expedited approval pathway for PDS0101, its lead candidate in HPV16-positive head and neck cancer.<h2 class="st-heading-2">FDA Meeting Request</h2>The company said the request follows a review of the final VERSATILE-002 trial data and a proposal to amend the ongoing VERSATILE-003 Phase 3 study. The amendment would reduce the number of patients while maintaining statistical power and add progression-free survival (PFS) as an earlier primary endpoint, alongside median overall survival (mOS).If the PFS endpoint is met, it could allow for an accelerated approval submission to the FDA. While the amendment is under review, the VERSATILE-003 trial will be temporarily paused, though treatment for currently enrolled patients will continue.<h2 class="st-heading-2">Almost 40 Months Of Median Survival</h2>CEO Frank Bedu-Addo said the final survival results from VERSATILE-002 were “very exciting,” noting that it was the first trial in the recurrent or metastatic head and neck cancer population to show a median overall survival of almost 40 months. He added that seeking to include PFS as an earlier primary endpoint could shorten the trial duration.Chief Medical Officer Kirk Shepard said the company’s goal is to pursue the fastest and most cost-effective regulatory path for approval and to provide a non-chemotherapy option for patients who currently lack effective therapies.<h2 class="st-heading-2">Trial Background</h2>VERSATILE-002 is an open-label, multi-center Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for unresectable, recurrent or metastatic HPV16-positive head and neck cancer.On Stocktwits, retail sentiment for PDS Biotechnology was ‘extremely bullish’ amid a 2,333% surge in 24-hour message volume.<h2 class="st-heading-2">Stocktwits Bulls Bet On Early FDA Nod</h2>One user said the news was “very good” and that the stock looked “way too cheap,” suggesting they were watching for more upside.<stembedurl>https://stocktwits.com/makedatbread88/message/634249334</stembedurl>Another user speculated that the FDA might allow an early approval if PDS agreed to continue trials at the same time, calling it a move that could give very sick head and neck cancer patients access to a potentially life-saving therapy.<stembedurl>https://stocktwits.com/Stockman824/message/634214470</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDS Biotechnology’s stock</a> has declined 38% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

PDS Biotechnology’s stock (PDSB) has declined 38% so far in 2025. | Image source: Getty Images

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

Equity

<ul class="summary-bullets"><li>Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.</li><li>Non-GAAP earnings rose to $2.61 per share, with operating margins improving despite restructuring and impairment charges.</li><li>Retail traders on Stocktwits turned bullish, setting upside targets between $170 and $200 for the stock.</li></ul>Shares of Align Technology rose about 16% in after-hours trading on Wednesday after the Invisalign maker reported third-quarter (Q3) revenue above its own forecast and showed improving momentum in clear aligners for teens and kids.<h2 class="st-heading-2">Results Beat Company Outlook</h2>Align reported Q3 revenue of $995.7 million, up 1.8% year over year and above its guidance range of $965 million to $985 million, though down 1.7% from the prior quarter as the company had flagged. Currency helped, adding about $15.6 million year on year.Clear Aligner revenue was $805.8 million, up 2.4% from a year earlier and flat sequentially. Total clear aligner volume rose 4.9% to 647,800 cases, with the biggest tailwind from younger patients.Treatments for teens and kids jumped 8.3% year over year and 14.7% from Q2 to 256,000 cases, helped by more doctors submitting cases and continued adoption of Invisalign First.The Imaging Systems and CAD/CAM business, which includes iTero scanners, brought in $189.9 million, down 0.6% year over year and 8.6% sequentially, which the company said was normal Q3 capital-equipment seasonality.<h2 class="st-heading-2">Profitability&nbsp;</h2>GAAP operating income was $96.3 million for an operating margin of 9.7%, lower than last year, mainly because the quarter included $88.3 million of restructuring, impairment and accelerated depreciation charges. On a non-GAAP basis, operating margin improved to 23.9%.Net income fell to $56.8 million, or $0.78 per share, from $1.55 a year earlier, largely because of those one-time charges. Non-GAAP EPS was $2.61, up from $2.35.Align ended the quarter with $1 billion in cash and cash equivalents, up from $901 million in the second quarter (Q2).<h2 class="st-heading-2">Outlook</h2>For the fourth quarter (Q4), Align expects revenue of $1.025 billion to $1.045 billion, with clear aligner volume, ASP and systems revenue all seen improving sequentially, and non-GAAP operating margin around 26%.&nbsp;For full-year 2025, the company still expects clear aligner volume to grow in the mid-single digits and revenue to be flat to slightly higher than 2024, reflecting a mixed dental market, especially in North America.<h2 class="st-heading-2">Stocktwits Users Cheer Align’s Strong Quarter</h2>On Stocktwits, retail sentiment for Align was ‘bullish’ amid ‘extremely high’ message volume.One user said Align remains the clear market leader after the quarter and that they were bullish on the stock getting back above $170 by year-end, with a price target of $200 by the first quarter of 2026.&nbsp;<stembedurl>https://stocktwits.com/durocali/message/634224575</stembedurl>Another user said the print was a big beat and flagged $155 as the level to watch on the upside, noting there were still higher gaps to be filled.<stembedurl>https://stocktwits.com/SpudZone/message/634224376</stembedurl><a href="https://stocktwits.com/symbol/ALGN">Align’s stock</a> has declined 37% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Align Technology logo is displayed on a smartphone with a S&P index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/980-iotecheportsullear2024inancialesultsandr20250327">reported</a> better-than-feared losses for 2024.PDS Biotechnology reported a loss per share of $1.03 for the year, narrower than the $1.39 reported for 2023 and better than an analyst estimate of $1.11, according to FinChat data.Net loss narrowed to $37.61 million in 2024 compared to $42.94 million in the prior year.The reduced losses, the company said, were primarily due to a decrease in operating expenses.Research and development expenses fell during the year to $22.6 million from $27.8 million a year ago, owing to reduced clinical costs, personnel costs, and professional fees.The company ended the year with a cash balance of $41.7 million.Last month, PDS Biotechnology announced an up to $22 million registered direct offering. The company said the securities purchase agreements with new and existing healthcare-focused institutional investors included $11 million of upfront gross proceeds.It also included up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.PDS is a late-stage immunotherapy company developing investigational products designed to stimulate and enhance targeted T cell responses against cancers.Earlier this month, the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to evaluate a combination of its investigational immunotherapy candidate Versamune MUC1 with a novel investigational tumor-targeting Interleukin 12 to treat colorectal carcinoma in certain patients who failed previous treatment.On Stocktwits, the retail investor sentiment about PDS Biotechnology dropped further into the ‘bearish’ territory (32/100), while message volume remained at the ‘extremely low’ level over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_12_26_56_PM_png_6c503f4d3f.webp" alt="PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>After the company released its earnings report, HC Wainwright analyst Joseph Pantginis lowered the firm’s price target to $13 from $21 while keeping a ‘Buy’ rating on the shares.A Stocktwits user, however, expressed optimism on the company.<stembedurl>https://stocktwits.com/AyR15/message/609402462</stembedurl>Another user opined that the results were “not as bad as predicted.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/609407057</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDSB shares</a> have lost over 25% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/toncoin-gains-outpace-bitcoin-ethereum-after-musk-grok-ai-goes-beyond-x-to-telegram/chJ2BLTRbEJ">Toncoin Gains Outpace Bitcoin, Ethereum After Musk’s Grok AI Goes Beyond X To Telegram – Retail’s Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.  

Uncovering Potential: PDS Biotechnology's Earnings Preview

PDS Biotechnology (PDSB) Receives a Buy from Noble Financial

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on PDS Biotechnology (PDSB Research Report) yesterday and set a price target of $1...

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults PR Newswire VANCOUVER, BC, May...

PDS Biotechnology (PDSB, $4.02) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that PDSB's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from B. Riley

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)s stock had its "buy" rating reiterated by analysts at B. Riley in a note issued to investors on Thursday, Benzinga reports. They presently...

PDS Biotechnology Co. (NASDAQ:PDSB) to Post Q1 2024 Earnings of ($0.40) Per Share, B. Riley Forecasts

PDS Biotechnology Co. (NASDAQ:PDSB  Free Report)  Analysts at B. Riley issued their Q1 2024 EPS estimates for PDS Biotechnology in a note issued to investors on Thursday, March 28th. B...

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.8405
Prev Close	$0.845
Open	$0.862
Dividend Yield	0.00%
50-Day Moving Average	$1.00
Beta	1.93
Avg. Volume	795,276.78
PE Ratio	-1.03

52-Week High	$2.46
52-Week Low	$0.84
Market Capitalization	$46.24M
EPS (Annual)	-$1.03
Price to Book	4.24
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PDSB
PDS Biotechnology Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PDSB News

PDSBPDS Biotechnology Corporation